CTMX Stock Analysis: Buy, Sell, or Hold?
CTMX - CytomX Therapeutics, Inc.
$3.15
0.11 (3.62%)
▲
5d:
+3.62%
30d:
-16.22%
90d:
-29.37%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When CTMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CTMX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CTMX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CTMX is currently trading at $3.15, which is considered fair relative to its 30-day fair value range of $2.97 to $3.62.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is approaching resistance at $3.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.50 (+296.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is approaching resistance at $3.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.50 (+296.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.97 -
$3.62
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 296.8% below Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$2.97 -
$3.62
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.82
Resistance Level
$3.22
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.49
Wall Street Target
$12.50
(+296.8%)
Revenue Growth (YoY)
-79.9%
Earnings Growth (YoY)
60.6%
Profit Margin
-166.4%
Share & Embed Analysis
Last updated: June 24, 2026 1:43 AM ET
Data refreshes hourly during market hours. Next update: 2:43 AM
Data refreshes hourly during market hours. Next update: 2:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTMX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Ogden
SELL
19323 shares
2026-03-17
Marcia Belvin
SELL
31492 shares
2026-03-17
Sean A Mccarthy
SELL
118969 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
